TW202317623A - 基於il2之治療劑及其使用方法 - Google Patents

基於il2之治療劑及其使用方法 Download PDF

Info

Publication number
TW202317623A
TW202317623A TW111121656A TW111121656A TW202317623A TW 202317623 A TW202317623 A TW 202317623A TW 111121656 A TW111121656 A TW 111121656A TW 111121656 A TW111121656 A TW 111121656A TW 202317623 A TW202317623 A TW 202317623A
Authority
TW
Taiwan
Prior art keywords
seq
fusion protein
amino acid
acid sequence
protein according
Prior art date
Application number
TW111121656A
Other languages
English (en)
Chinese (zh)
Inventor
吳家曦
尼可林 布洛赫
張彤
家楊 林
塞繆爾 戴維斯
艾瑞克 史密斯
艾麗卡 烏爾曼
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW202317623A publication Critical patent/TW202317623A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111121656A 2021-06-14 2022-06-10 基於il2之治療劑及其使用方法 TW202317623A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163210111P 2021-06-14 2021-06-14
US63/210,111 2021-06-14
US202263365375P 2022-05-26 2022-05-26
US63/365,375 2022-05-26

Publications (1)

Publication Number Publication Date
TW202317623A true TW202317623A (zh) 2023-05-01

Family

ID=82361286

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111121656A TW202317623A (zh) 2021-06-14 2022-06-10 基於il2之治療劑及其使用方法

Country Status (12)

Country Link
US (1) US12528851B2 (enExample)
EP (1) EP4355427A1 (enExample)
JP (1) JP2024521472A (enExample)
KR (1) KR20240021194A (enExample)
AU (1) AU2022292792A1 (enExample)
BR (1) BR112023023787A2 (enExample)
CL (2) CL2023003730A1 (enExample)
CO (1) CO2023015593A2 (enExample)
IL (1) IL308369A (enExample)
MX (1) MX2023014905A (enExample)
TW (1) TW202317623A (enExample)
WO (1) WO2022266598A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CN119654338A (zh) 2022-06-04 2025-03-18 再生元制药公司 白细胞介素-2蛋白质原及其用途
AU2023308064A1 (en) * 2022-07-11 2025-02-27 Genuv Inc. Cytokine fusion protein
IL320128A (en) * 2022-10-31 2025-06-01 Regeneron Pharma Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine
EP4491631A1 (en) * 2023-07-13 2025-01-15 Anaveon AG Anti-pd-1 antibody binding domain and immunoconjugate
EP4431525A1 (en) * 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
EP4791777A1 (en) 2023-10-09 2026-08-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine
EP4791504A1 (en) 2023-10-09 2026-08-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025218606A1 (zh) * 2024-04-16 2025-10-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1362062A (en) 1920-02-16 1920-12-14 American Sanitary Works Water-closet bowl
US2882777A (en) 1955-11-03 1959-04-21 Leland Gifford Co Hydraulic tracing apparatus
US3233920A (en) 1963-02-27 1966-02-08 Mueller Co Insulated pipe joint
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PL3351261T3 (pl) 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
SG11201509595PA (en) 2013-05-28 2015-12-30 Dcb Usa Llc Antibody locker for the inactivation of protein drug
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
GB2527075A (en) 2014-03-17 2015-12-16 Daassist As Percutaneous system, devices and methods
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
MX383464B (es) * 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
CN108697798A (zh) 2016-02-16 2018-10-23 达纳-法伯癌症研究所有限公司 免疫疗法组合物及方法
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2018226750A1 (en) 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
KR20240115352A (ko) 2017-12-06 2024-07-25 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
MX387358B (es) * 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
WO2019168791A2 (en) 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CU24554B1 (es) 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
BR112020025287A2 (pt) 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2020061142A1 (en) 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CA3114179A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EP3897746A4 (en) 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3897690A4 (en) 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
SG11202111409YA (en) 2019-05-20 2021-12-30 Cytune Pharma IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
AU2020285636A1 (en) 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020259536A1 (zh) 2019-06-24 2020-12-30 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
KR20260089650A (ko) 2019-07-12 2026-06-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
AU2020329933A1 (en) 2019-08-15 2022-03-24 Cytimm Therapeutics, Inc. Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
CN114728179A (zh) 2019-08-19 2022-07-08 潘迪恩运营公司 利用pd-1激动剂的靶向免疫耐受
WO2021055568A1 (en) 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021168192A2 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4172216A4 (en) * 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法

Also Published As

Publication number Publication date
MX2023014905A (es) 2024-02-14
CL2023003730A1 (es) 2024-07-05
US20220402989A1 (en) 2022-12-22
BR112023023787A2 (pt) 2024-02-20
US12528851B2 (en) 2026-01-20
CL2024003382A1 (es) 2025-03-28
KR20240021194A (ko) 2024-02-16
WO2022266598A1 (en) 2022-12-22
AU2022292792A1 (en) 2024-01-04
CO2023015593A2 (es) 2023-11-30
IL308369A (en) 2024-01-01
JP2024521472A (ja) 2024-05-31
EP4355427A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US12528851B2 (en) IL2-based therapeutics and methods of use thereof
JP7690552B2 (ja) ＣＤ１３７抗原結合部位を含むＦｃ結合断片
US12344672B2 (en) Antibody molecules that bind PD-L1 and CD137
JP7489316B2 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
CN108884164B (zh) 用于免疫疗法的经修饰细胞
JP7603205B2 (ja) 抗体分子
JP7474235B2 (ja) ＯＸ４０抗原結合部位を含むＦｃ結合断片
TW202400654A (zh) 抗tigit抗體及其作為治療和診斷的用途
JP2020518622A (ja) Ｏｘ４０およびｃｔｌａ−４に対する二重特異性抗体
KR20190130137A (ko) 종양 특이적 세포 고갈을 위한 fc-최적화된 항-cd25
JP2018520650A (ja) 新規のポリペプチド
JP7674278B2 (ja) 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法
EP3969474A1 (en) Binding molecules
CN116194471A (zh) 抗pd-1抗体和融合蛋白
TW202200615A (zh) 用於治療和預防患者的crs之方法
CN117940462A (zh) 基于il2和抗pd-1的双特异性治疗及其使用方法
CA3171061A1 (en) Il2-based therapeutics and methods of use thereof
EA052561B1 (ru) Терапевтические средства на основе il-2 и анти-pd-1 и способы их применения
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
US20250114469A1 (en) METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
WO2026103838A1 (en) Polypeptide complexes comprising il-21 variants and uses thereof
US20250114468A1 (en) Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
JP2024534838A (ja) ＮＫｐ４６結合ポリペプチド及びその使用
CN114605538A (zh) 靶向cd19的人源化抗体及其用途